The role of adjuvant therapy in melanoma management

Cancer

Volumn 75, Issue 2 S, 1995, Pages 726-734

  Barth, Andreas ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

immunotherapy; interferon; levamisole; melanoma

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; DACARBAZINE; GANGLIOSIDE; LEVAMISOLE; MEGESTROL ACETATE; MELPHALAN; TUMOR VACCINE;

ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG THERAPY; HUMAN; MELANOMA; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES;

BACTERIAL VACCINES; BCG VACCINE; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; HUMAN; IMMUNOTHERAPY, ACTIVE; INTERFERON TYPE II; INTERFERON-ALPHA; LEVAMISOLE; MEGESTROL; MEGESTROL ACETATE; MELANOMA; PERFUSION, REGIONAL; PROPIONIBACTERIUM ACNES; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028567024     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950115)75:2+<726::AID-CNCR2820751417>3.0.CO;2-R     Document Type: Article

References (82)

1. I Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness
2. Scientific basis for adjuvant and primary (neoadju‐vant) chemotherapy
3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
4. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
5. Immunological factors which influence response to immunotherapy in malignant melanoma
6. BCG immunotherapy of malignant melanoma: summary of a seven‐year experience
7. The significance of conversion of skin reactivity to efficacy of bacillus Calmette‐Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients
8. Adjuvant reactivity predicts survival in patients with “high‐risk” primary malignant melanoma treated with systemic BCG
9. Pooled analysis of the efficacy of bacille Calmette‐Guerin (BCG) immunotherapy in malignant melanoma
10. Long‐term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non‐treatment in a randomised multicentre study (EORTC protocol 18781.rpar;
11. Adjuvant BCG immunotherapy for malignant melanoma
12. A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and stage II cutaneous melanoma: an interim report
13. Adjuvant immunotherapy or chemotherapy for malignant melanoma: preliminary report of the National Cancer Institute randomized trial
14. BCG immunotherapy in stage I melanoma patients: does it influence prognosis determined by HLA‐DR expression in high‐risk primary tumors?
15. Adjuvant immunotherapy of malignant melanoma
16. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma
17. Adjuvant immunotherapy of malignant melanoma: status of clinical trials at UCLA
18. Randomized trial of adjuvant therapy for “high‐risk” primary malignant melanoma
19. Surgical adjuvant immunotherapy with BCG in patients with malignant melanoma: results of a prospective, randomized trial
20. Intralymphatic and regional surgical adjuvant immunotherapy in high‐risk melanoma of the extremities
21. A randomized prospective clinical trial of adjuvant C. parvum. immunotherapy in 260 patients with clinically localized melanoma (stage I): prognostic factors analysis and preliminary results of immunotherapy
22. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma
23. A randomized prospective comparison of BCG versusC. parvum. adjuvant immunotherapy in melanoma patients with resected metastatic lymph nodes
24. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma [abstract]
25. Corynebacterium parvum versus bacille Calmette‐Guérin adjuvant immunotherapy of stage II malignant melanoma
26. An assessment of DTIC versus levamisole or placebo in the treatment of high risk stage I patients after surgical removal of a primary melanoma of the skin: a phase III adjuvant study (EORTC protocol 18761)
27. DTIC and combination therapy for melanoma. III: DTIC (NSC 45388) Surgical Adjuvant Study COG protocol 7040
28. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases
29. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma
30. Randomized trial of high‐dose chemotherapy with autologous bone marrow support as adjuvant therapy for high‐risk, multi‐node‐positive malignant melanoma
31. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit
32. Perfusion for malignant melanoma of the extremities
33. Hyperthermic perfusion with chemotherapy for cancer of the extremities
34. Results of hyperthermic perfusion for melanoma of the extremities
35. Hyperthermic regional perfusion for melanoma of the limbs
36. Hyperthermic perfusion with chemotherapy for melanoma of the extremities
37. Phase III adjuvant studies in operable malignant melanoma
38. Fraction size in external beam radiation therapy in the treatment of melanoma
39. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study
40. Regional radiotherapy as adjuvant treatment for head and neck malignant melanoma: preliminary results
41. A prospective, randomized controlled trial of megestrol acetate among high‐risk patients with resected malignant melanoma
42. Double‐blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma
43. A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma
44. Improved survival in patients with poor prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada clinical trials group
45. Levamisole as adjuvant therapy for melanoma: quo vadis?
46. Spontaneous regression of melanoma: report of a case
47. Spontaneous regression of human melanoma: clinical and experimental studies
48. Risk factors for cutaneous melanoma: a practical method of recognizing predisposed individuals
49. Demonstration of antibodies against human malignant melanoma by immunofluorescence
50. Local therapy with biologic agents: intralesional therapy
51. A membrane antigen common to human cancer and fetal brain tissue
52. Ganglioside GM2 as a human tumor antigen (OFA‐I‐1)
53. Identification of a human neuroectodermal tumor antigen (OFA‐1‐2) as ganglioside GD2
54. Structural characterization of human melanoma‐associated antigen p97 with monoclonal antibodies
55. Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 635.40S to human melanoma cells
56. Human antibody to OFA‐1, a tumor antigen produced in vitro by EBV‐transformed human B‐lymphoblastoid cell lines
57. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2
58. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases
59. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen
60. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma
61. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
62. Human gene MAGE‐3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
63. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA‐A2 melanomas
64. Melanocyte lineage‐specific antigen gp 100 is recognized by melanoma‐derived tumor‐infiltrating lymphocytes
65. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
66. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
67. Treatment of metastatic melanoma with an autologous tumor‐cell vaccine: clinical and immunological results in 64 patients
68. Active specific immunotherapy of melanoma with allogeneic cell lysates: rationale, results, and possible mechanisms of action
69. Evidence that treatment with vaccinia melanoma lysates (VMCL) may improve survival of patients with stage II melanoma: treatment of stage II melanoma with viral lysates
70. Polyvalent melanoma cell vaccine induces delayed‐type hypersensitivity and in vitro cellular immune response
71. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma
72. Cancer vaccines get a shot in the arm
73. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside
74. A phase III randomized multi‐institutional double blind adjuvant study of vaccinia melanoma oncolysate (VMO) vs. vaccinia (V) alone in stage II melanoma
75. Cutaneous melanoma
76. Studies of interferons in the therapy of melanoma
77. Recombinant human interferon gamma: adverse effects in high‐risk stage I and II cutaneous malignant melanoma [letter]
78. The histogenesis and biological behavior of primary human malignant melanoma of the skin
79. Thickness, cross‐sectional areas and depth of invasion in the prognosis of cutaneous melanoma
80. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA‐A2 melanomas
81. Results of adjuvant interferon study in WHO melanoma programme [letter)